AMRI Key Stats
- Nasdaq stocks posting largest percentage decreases May 22
- Albany Molecular Research Management Presents at UBS Global Healthcare (Transcri... May 22
- ALBANY MOLECULAR RESEARCH INC Financials May 17
- The Son of the Father of Indexing is Beating the Index Again This Year May 15
- AMRI CFO to Present at the UBS Global Healthcare Conference PR Newswire May 15
- ALBANY MOLECULAR RESEARCH INC Files SEC form 10-Q, Quarterly Report May 9
- ALBANY MOLECULAR RESEARCH INC Files SEC form 8-K, Results of Operations and Fina... May 8
- Albany Molecular Research's CEO Discusses Q1 2013 Results - Earnings Call Transc... May 7
- Albany Molecular Research (AMRI) Reports Q1 EPS of $0.23 Street Insider May 7
- AMRI Announces First Quarter 2013 Results and Raises EPS Guidance for the Year PR Newswire May 7
AMRI Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Albany Molecular Research is up 288.9% over the last year vs S&P 500 Total Return up 28.49%, Cambrex Corporation up 79.20%, and Achillion Pharmaceuticals up 10.97%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Income Statement View Statement
Pro Ratings for AMRI
Pro Report PDF for AMRI
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download AMRI Pro Report PDF
Pro Strategies Featuring AMRI
Did Albany Molecular Research make it into our Pro Portfolio Strategies?